Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft

Bone Marrow Transplantation volume 28, pages 1083–1086 (2001)Cite this article

Abstract

A 51-year-old patient with refractory CLL elected to participate in a trial of nonmyeloablative trans- plantation from an HLA-matched unrelated donor. He received low-dose fludarabine/TBI, with infusion of donor PBPC and cyclosporin (CsA)/MMF. Early post transplant he experienced explosive tumor growth with respiratory insufficiency. After immunosuppression discontinuation and rituximab administration, no response was observed. This prompted treatment with cyclophosphamide (2 g/m2/day × 2), paclitaxel (250 mg/m2 over 24 h), doxorubicin (50 mg/m2), solumedrol (500 mg/day), and a second dose of rituximab, from days +11 to +14. A rapid response was achieved. Chemotherapy did not cause an obvious compromise of donor stem cell engraftment or establishment of stable donor chimerism.

Bone Marrow Transplantation (2001) 28, 1083–1086.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Carella AM, Champlin R, Slavin S et al. Mini-allografts: ongoing trials in humans Bone Marrow Transplant 2000 25: 345–350

    Article  CAS  PubMed  Google Scholar 

  2. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 2001 97: 3390–3400

    Article  CAS  PubMed  Google Scholar 

  3. Niederwieser DW, McSweeney P, Wolff D et al. Hematopoietic stem cell transplants (HSCT) from unrelated donors using low dose TBI, fludarabine and a combination of cyclosporine and mycophenolate Proc Am Soc Clin Oncol 2000 19: 47a

    Google Scholar 

  4. Colson YL, Wren SM, Schuchert MJ et al. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers J Immunol 1995 155: 4179–4188

    CAS  PubMed  Google Scholar 

  5. Mayumi H, Umesue M, Nomoto K . Cyclophosphamide-induced immunological overview: an overview Immunobiology 1996 195: 129–139

    Article  CAS  PubMed  Google Scholar 

  6. Demirer T, Rowley S, Buckner CD et al. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer J Clin Oncol 1995 13: 1714–1719

    Article  CAS  PubMed  Google Scholar 

  7. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer Blood 1992 79: 3036–3044

    CAS  PubMed  Google Scholar 

  8. deMagalhaes-Silverman M, Bloom E, Lembersky B et al. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer Clin Cancer Res 1997 3: 193–197

    CAS  PubMed  Google Scholar 

  9. Rahman Z, Kavanagh J, Champlin R et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer Clin Cancer Res 1998 4: 2717–2121

    CAS  PubMed  Google Scholar 

  10. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial Blood 1989 73: 1729–1734

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Colorado Bone Marrow Transplant Program, Denver, CO, USA

    Y Nieto, SI Bearman, EJ Shpall, RB Jones, PJ Cagnoni & PA McSweeney

  2. Radiation Therapy Department, University of Colorado, Denver, CO, USA

    RA Rabinovitch

Authors
  1. Y Nieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. SI Bearman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. EJ Shpall
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. RB Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. PJ Cagnoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. RA Rabinovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. PA McSweeney
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieto, Y., Bearman, S., Shpall, E. et al. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. Bone Marrow Transplant 28, 1083–1086 (2001). https://doi.org/10.1038/sj.bmt.1703293

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703293

Keywords

This article is cited by

Search

Advanced search

Quick links